PLEXYMER, INC.

Biotech · Private

AI-powered platform for antibody drug formulation optimization, paired with laboratory robotics to accelerate development of subcutaneous injection formulations

Grants
$305K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase I · SBIR Phase I: AI-Directed Automation for Accelerated Bioformulation of Antibody Therapeutics$305,000
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2134Mahzi Therapeutics Inc.—$27M
2135INVIVO THERAPEUTICS HOLDINGS CORP.—$9.3M
2136Richard Fisher——
2137PLEXYMER, INC.——
2138SGN, Inc.—$3.8M
2139NOVATARG, INC.——
2140Helix Alternative Technologies Inc.—$6.0M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.